Skip to content
Catalyst

pantothenic acidWhat was measured

Measured, with no finding

98 endpoints

Show what was measuredHide what was measured
  • development of dilated cardiomyopathy

    no effect

    In our patients, long-term treatment has failed to reduce the number of infectious episodes and prevent dilated cardiomyopathy

    PMID 14654353 · one of two readings recorded this

  • number of infectious episodes

    no effect

    In our patients, long-term treatment has failed to reduce the number of infectious episodes and prevent dilated cardiomyopathy

    PMID 14654353 · one of two readings recorded this

  • baseline nutrient intakes, cognitive decline versus intact cognition

    no effect

    However, no significant associations between cognitive decline and nutrient intakes were observed among women

    PMID 27427336 · one of two readings recorded this

  • baseline pantothenate intake, cognitive decline versus intact cognition

    decreases

    Compared with men with intact cognition, the men with cognitive decline had lower baseline intakes of calcium, vitamin A, vitamin B2 , pantothenate, soluble fiber, green vegetables and milk

    PMID 27427336 · one of two readings recorded this

  • cognitive decline (decrease in Mini-Mental State Examination score)

    increases

    we found that cognitive decline was significantly associated with low intakes of carotene, vitamin B2 , pantothenate, calcium and green vegetables

    PMID 27427336 · one of two readings recorded this

  • C-reactive protein concentration at the third visit

    decreases, p = 0.0004, n = 908

    P for trend = <0.0001, β = -0.11 (P-value = 0.0004) for PA average (baseline, 2nd, 3rd)

    PMID 28739188 · one of two readings recorded this

  • C-reactive protein concentration at the third visit

    decreases, p = 0.001, n = 908

    P for trend = 0.001, β = -0.07 (P-value = 0.001) for PA baseline

    PMID 28739188 · one of two readings recorded this

  • change in C-reactive protein concentration from baseline to the third visit

    decreases, p = 0.001, n = 908

    P for trend = 0.001, β = -0.35 (P-value = 0.001) for PA average (baseline, 2nd, 3rd)

    PMID 28739188 · one of two readings recorded this

  • change in C-reactive protein concentration from baseline to the third visit

    decreases, p = 0.002, n = 908

    P for trend = 0.002, β = -0.24 (P-value = 0.002) for PA baseline

    PMID 28739188 · one of two readings recorded this

  • brain vitamin B5 concentration

    decreases

    We found that widespread, severe cerebral deficiency of vitamin B5 occurs in AD

    PMID 32416962 · one of two readings recorded this

  • brain vitamin B5 concentration

    decreases

    This deficiency was worse in those regions known to undergo severe damage, including the hippocampus, entorhinal cortex, and middle temporal gyrus

    PMID 32416962 · one of two readings recorded this

  • endogenous vitamin B5 concentration in seven post-mortem brain regions, Alzheimer's disease cases vs controls, gas chromatography-mass spectrometry

    decreases

    Not recorded as a finding: the compound is what was measured, not what was given

    We found that widespread, severe cerebral deficiency of vitamin B5 occurs in AD.

    PMID 32416962 · one of two readings recorded this

  • all-cause mortality (hazard ratio, enalapril-folic acid vs enalapril)

    no effect, p = 0.47

    The enalapril‐folic acid group had 302 all‐cause fatalities (2.9 %) compared to 320 (3.1 %) in the enalapril group (HR = 0.94; 95% CI: 0.81‐1.10; p =.47)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, per SD of plasma vitamin B5)

    no effect, p = 0.114, n = 1010

    Vitamin B5, ng/mL (Per SD) | 1010 | 505(50.0) | 1.31(0.99,1.74) |.060 | 1.21(0.96,1.52) |.114

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, per SD of plasma vitamin B5)

    no effect, p = 0.06, n = 1010

    Vitamin B5, ng/mL (Per SD) | 1010 | 505(50.0) | 1.31(0.99,1.74) |.060 | 1.21(0.96,1.52) |.114

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    increases

    When Q4‐Q5 were combined, a significant 41% increment (OR = 1.41, 95% CI: 1.03‐1.95) in all‐cause death risk was found compared with Q1‐Q3

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    increases, p = 0.002, n = 404

    Q4 ‐ Q5 (≥ 45.7) | 404 | 225(55.70) | 1.53(1.17,2.00) |.002 | 1.41(1.03,1.95) |.034

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    < 66.4 | 327 | 161(49.2) | 178 | 92(51.7) | 0.92(0.61,1.38)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    < 164.7 | 301 | 126(41.9) | 199 | 105(52.8) | 1.48(0.98,2.24)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    increases

    < 23.3 | 296 | 136(45.9) | 209 | 125(59.8) | 1.56(1.04,2.34)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    increases

    < 90.4 | 253 | 110(43.5) | 244 | 142(58.2) | 1.85(1.24,2.76)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    < 5.3 | 287 | 135(47.0) | 210 | 108(51.4) | 0.99(0.66,1.50)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    Female | 351 | 167(47.6) | 247 | 132(53.4) | 1.24(0.85,1.79)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    < 6.0 | 194 | 101(52.1) | 113 | 59(52.2) | 0.67(0.38,1.18)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    Male | 255 | 113(44.3) | 157 | 93(59.2) | 1.46(0.91,2.35)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    Anqing | 230 | 108(47.0) | 200 | 107(53.5) | 1.16(0.73,1.82)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    Lianyungang | 376 | 172(45.7) | 204 | 118(57.8) | 1.38(0.93,2.05)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    < 13.8 | 323 | 142(44.0) | 175 | 92(52.6) | 1.37(0.90,2.08)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    < 0.2 | 324 | 142(43.8) | 174 | 92(52.9) | 1.33(0.87,2.01)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    < 5.2 | 286 | 144(50.3) | 210 | 115(54.8) | 1.12(0.75,1.69)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    Enalapril‐folic acid | 283 | 130(45.9) | 193 | 108(56.0) | 1.47(0.97,2.22)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 Q4-Q5 vs Q1-Q3)

    no effect

    Enalapril | 323 | 150(46.4) | 211 | 117(55.5) | 1.20(0.80,1.79)

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 quintiles)

    no effect, p = 0.257, n = 202

    Q2 (32.9 ‐ < 38.9) | 202 | 95(47.0) | 1.22(0.82,1.79) |.324 | 1.29(0.83,2.01) |.257

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 quintiles)

    no effect, p = 0.324, n = 202

    Q2 (32.9 ‐ < 38.9) | 202 | 95(47.0) | 1.22(0.82,1.79) |.324 | 1.29(0.83,2.01) |.257

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 quintiles)

    no effect, p = 0.395, n = 202

    Q3 (38.9 ‐ < 45.7) | 202 | 98(48.5) | 1.33(0.89,1.97) |.162 | 1.22(0.77,1.94) |.395

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 quintiles)

    no effect, p = 0.162, n = 202

    Q3 (38.9 ‐ < 45.7) | 202 | 98(48.5) | 1.33(0.89,1.97) |.162 | 1.22(0.77,1.94) |.395

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 quintiles)

    no effect, p = 0.051, n = 202

    Q4 (45.7‐ < 55.0) | 202 | 107(53.0) | 1.63(1.07,2.48) |.023 | 1.62(1.00,2.62) |.051

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 quintiles)

    increases, p = 0.023, n = 202

    Q4 (45.7‐ < 55.0) | 202 | 107(53.0) | 1.63(1.07,2.48) |.023 | 1.62(1.00,2.62) |.051

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 quintiles)

    increases, p = 0.03, n = 202

    Q5 (≥ 55.0) | 202 | 118(58.4) | 2.06(1.34,3.15) | <.001 | 1.77(1.06,2.95) |.03

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 quintiles)

    increases, p = 0.001, n = 202

    Q5 (≥ 55.0) | 202 | 118(58.4) | 2.06(1.34,3.15) | <.001 | 1.77(1.06,2.95) |.03

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 tertiles)

    no effect, p = 0.068, n = 336

    T2 (37.1‐ < 8.4) | 336 | 171(50.9) | 1.39(1.03,1.87) |.032 | 1.37(0.98,1.92) |.068

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 tertiles)

    increases, p = 0.032, n = 336

    T2 (37.1‐ < 8.4) | 336 | 171(50.9) | 1.39(1.03,1.87) |.032 | 1.37(0.98,1.92) |.068

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 tertiles)

    increases, p = 0.027, n = 337

    T3 (≥ 48.4) | 337 | 187(55.5) | 1.80(1.28,2.54) | <.001 | 1.58(1.05,2.38) |.027

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality (odds ratio, vitamin B5 tertiles)

    increases, p = 0.001, n = 337

    T3 (≥ 48.4) | 337 | 187(55.5) | 1.80(1.28,2.54) | <.001 | 1.58(1.05,2.38) |.027

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality, p for trend across vitamin B5 tertiles

    increases, p = 0.024

    P for trend | <.001 |.024

    PMID 35699663 · one of two readings recorded this

  • all-cause mortality, trend across vitamin B5 quintiles

    increases, p = 0.022

    The trend test was significant (p =.022)

    PMID 35699663 · one of two readings recorded this

  • plasma vitamin B5 concentration

    increases, p = 0.001

    Vitamin B5, ng/mL b | 41.9 (34.8, 52.0) | 40.9 (33.9, 50.3) | 43.7 (36.1, 53.9) |.001

    PMID 35699663 · one of two readings recorded this

  • pantothenic acid concentration

    no effect, p = 0.1

    CB | 69.1±31.7 (49.9–88.3) | 47.1±21.3 (32.8–61.4) | 0.7 | 0.1 | 3.1 | 2.9 | 1.8 (0.7–4.7) | 1.0 | –0.7

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid concentration

    no effect, p = 0.09

    CG | 35.3±16.2 (26.3–44.3) | 25.2±8.6 (20.2–30.2) | 0.7 | 0.09 | 4.5 | 2.2 | 1.4 (0.7–3.1) | 1.0 | –0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid concentration

    decreases, p = 0.0001

    HP | 91.5±28.7 (73.3–109.8) | 49.4±17.8 (39.1–59.7) | 0.5 | <0.0001 | 11.5 | 3.5 | 2.1 (1.02–4.2) | 1.2 | –1.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid concentration

    no effect, p = 0.2

    MED | 27.3±13.7 (19.4–35.2) | 20.4±10.1 (14.5–26.2) | 0.8 | 0.2 | 2.3 | 1.6 | 1.2 (0.5–2.7) | 1.0 | –0.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid concentration

    decreases, p = 0.02

    MTG | 47.1±22.9 (34.5–59.8) | 29.7±18.9 (13.9–24.3) | 0.6 | 0.02 | 6.0 | 3.4 | 2.0 (0.9–4.5) | 1.0 | –0.8

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid concentration

    decreases, p = 0.007

    MCX | 84.1±42.0 (61.7–106.5) | 45.0±21.5 (32.1–58.0) | 0.5 | 0.007 | 8.1 | 4.9 | 2.7 (1.3–5.8) | 1.8 | –0.9

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid concentration

    decreases, p = 0.002

    PONS | 32.6±15.4 (19.7–45.4) | 29.3±7.5 (23.0–35.5) | 0.9 | 0.002 | 9.3 | 8.8 | 4.7 (1.7–12.7) | 2.8 | –1.2

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid concentration

    decreases, p = 0.008

    PVC | 91.5±46.5 (65.7–117.2) | 48.6±20.2 (36.4–60.8) | 0.5 | 0.008 | 7.9 | 3.3 | 1.9 (0.97–3.8) | 1.0 | –0.9

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid concentration

    no effect, p = 0.09

    PUT | 140.6±89.5 (86.5–194.7) | 81.8±40.9 (58.2–105.3) | 0.6 | 0.09 | 4.5 | 3.1 | 1.9 (0.7–4.7) | 1.0 | –0.7

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid concentration

    decreases, p = 0.004

    SN | 58.9±25.5 (42.7–75.0) | 29.7±11.8 (21.8–37.6) | 0.5 | 0.004 | 8.0 | 4.9 | 2.7 (1.2–6.2) | 1.7 | –1.2

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    CB | 0.7 | 0.6 | 0.5 | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    CG | 0.7 | 0.8 | 0.5 | 0.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    ENT | – | – | 0.4 | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    HP | 0.5 | 0.9 | 0.5 | 0.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    MTG | 0.6 | 0.9 | 0.5 | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    MCX | 0.5 | 0.8 | 0.3 | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    PVC | 0.5 | 0.9 | 0.4 | 0.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    CB | 0.7 | 0.6 | 0.5 | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    CG | 0.7 | 0.8 | 0.5 | 0.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    ENT | – | – | 0.4 | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    GP | – | – | – | 0.4

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    HP | 0.5 | 0.9 | 0.5 | 0.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    MFG | – | – | – | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    MTG | 0.6 | 0.9 | 0.5 | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    MCX | 0.5 | 0.8 | 0.3 | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    PVC | 0.5 | 0.9 | 0.4 | 0.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    PUT | 0.6 | – | – | 0.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    SN | 0.5 | 0.6 | – | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    CB | 0.7 | 0.6 | 0.5 | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    CG | 0.7 | 0.8 | 0.5 | 0.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    HP | 0.5 | 0.9 | 0.5 | 0.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    MED | 0.7 | 0.6 | – | –

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    MTG | 0.6 | 0.9 | 0.5 | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    MCX | 0.5 | 0.8 | 0.3 | 0.6

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    PONS | 0.9 | 0.7 | – | –

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    PVC | 0.5 | 0.9 | 0.4 | 0.5

    PMID 38820022 · one of two readings recorded this

  • pantothenic acid fold-change (cases vs controls)

    unclear

    SN | 0.5 | 0.6 | – | 0.6

    PMID 38820022 · one of two readings recorded this

  • risk ratio of case values below control 95% CI lower limit

    unclear

    CB | 69.1±31.7 (49.9–88.3) | 47.1±21.3 (32.8–61.4) | 0.7 | 0.1 | 3.1 | 2.9 | 1.8 (0.7–4.7) | 1.0 | –0.7

    PMID 38820022 · one of two readings recorded this

  • risk ratio of case values below control 95% CI lower limit

    unclear

    CG | 35.3±16.2 (26.3–44.3) | 25.2±8.6 (20.2–30.2) | 0.7 | 0.09 | 4.5 | 2.2 | 1.4 (0.7–3.1) | 1.0 | –0.6

    PMID 38820022 · one of two readings recorded this

  • risk ratio of case values below control 95% CI lower limit

    decreases

    HP | 91.5±28.7 (73.3–109.8) | 49.4±17.8 (39.1–59.7) | 0.5 | <0.0001 | 11.5 | 3.5 | 2.1 (1.02–4.2) | 1.2 | –1.5

    PMID 38820022 · one of two readings recorded this

  • risk ratio of case values below control 95% CI lower limit

    unclear

    MED | 27.3±13.7 (19.4–35.2) | 20.4±10.1 (14.5–26.2) | 0.8 | 0.2 | 2.3 | 1.6 | 1.2 (0.5–2.7) | 1.0 | –0.5

    PMID 38820022 · one of two readings recorded this

  • risk ratio of case values below control 95% CI lower limit

    unclear

    MTG | 47.1±22.9 (34.5–59.8) | 29.7±18.9 (13.9–24.3) | 0.6 | 0.02 | 6.0 | 3.4 | 2.0 (0.9–4.5) | 1.0 | –0.8

    PMID 38820022 · one of two readings recorded this

  • risk ratio of case values below control 95% CI lower limit

    decreases

    MCX | 84.1±42.0 (61.7–106.5) | 45.0±21.5 (32.1–58.0) | 0.5 | 0.007 | 8.1 | 4.9 | 2.7 (1.3–5.8) | 1.8 | –0.9

    PMID 38820022 · one of two readings recorded this

  • risk ratio of case values below control 95% CI lower limit

    decreases

    PONS | 32.6±15.4 (19.7–45.4) | 29.3±7.5 (23.0–35.5) | 0.9 | 0.002 | 9.3 | 8.8 | 4.7 (1.7–12.7) | 2.8 | –1.2

    PMID 38820022 · one of two readings recorded this

  • risk ratio of case values below control 95% CI lower limit

    unclear

    PVC | 91.5±46.5 (65.7–117.2) | 48.6±20.2 (36.4–60.8) | 0.5 | 0.008 | 7.9 | 3.3 | 1.9 (0.97–3.8) | 1.0 | –0.9

    PMID 38820022 · one of two readings recorded this

  • risk ratio of case values below control 95% CI lower limit

    unclear

    PUT | 140.6±89.5 (86.5–194.7) | 81.8±40.9 (58.2–105.3) | 0.6 | 0.09 | 4.5 | 3.1 | 1.9 (0.7–4.7) | 1.0 | –0.7

    PMID 38820022 · one of two readings recorded this

  • risk ratio of case values below control 95% CI lower limit

    decreases

    SN | 58.9±25.5 (42.7–75.0) | 29.7±11.8 (21.8–37.6) | 0.5 | 0.004 | 8.0 | 4.9 | 2.7 (1.2–6.2) | 1.7 | –1.2

    PMID 38820022 · one of two readings recorded this

  • heart rate, respiratory gas exchange, perceived exertion, blood lactate, glucose and free fatty acids during 50-km ride

    no effect

    There were no significant differences in any of the measured parameters between experimental conditions

    PMID 9650731 · one of two readings recorded this

  • time to complete 2000-m time trial

    no effect, p = 0.58

    Time to complete the 2000-m time trial was also not significantly different between experimental conditions [PL 178.2 (8.4), AP 170.7 (10.2) s; P=0.58]

    PMID 9650731 · one of two readings recorded this

  • time to complete a 2000-m cycle ergometer time trial after a 50-km steady-state ride

    no effect, PL 178.2 (8.4) s vs AP 170.7 (10.2) s, p = 0.58

    Not recorded as a finding: the intervention held more than the compound

    Time to complete the 2000-m time trial was also not significantly different between experimental conditions [PL 178.2 (8.4), AP 170.7 (10.2) s; P=0.58].

    PMID 9650731 · one of two readings recorded this

  • time to complete a 2000-m cycle time trial after a 50-km steady-state ride

    no effect, PL 178.2 (8.4) s vs AP 170.7 (10.2) s, p = 0.58, n = 6

    Not recorded as a finding: the intervention held more than the compound

    Time to complete the 2000-m time trial was also not significantly different between experimental conditions [PL 178.2 (8.4), AP 170.7 (10.2) s; P=0.58].

    PMID 9650731 · one of two readings recorded this